Skip to main content

Biomarkers in Drug Discovery and Development: Pre-analytical and Analytical Considerations

  • Chapter
  • First Online:
Translating Molecular Biomarkers into Clinical Assays

Part of the book series: AAPS Advances in the Pharmaceutical Sciences Series ((AAPS,volume 21))

Abstract

Today biomarkers are used widely across the drug development continuum to improve the success rate and cost-effectiveness of rational drug development [1, 2]. These include diagnostic indicators of disease, assessments for biological pathways for new therapeutics, confirmation of target engagement or mechanism-of-action, safety indicators, and as pharmacodynamic (PD) measures of therapeutic efficacy [1, 2]. The application of biomarkers is now commonplace in drug development and has helped usher in a new era of predictive, preventative, and personalized medicine, where therapeutics can be tailored to a patient’s unique biology. However, prior to being used for these purposes, there are several practical aspects of biomarker utilization that need to be taken into account. These include biomarker validation and qualification. Analytical validation is the formal process of evaluating an assay to ensure it provides reliable data [1, 2], whereas qualification (also known as clinical validation) is the evidentiary process of linking a biomarker with biology, pharmacology, or clinical endpoint [1, 2]. Analytical validation is important, as issues of quality herein can limit the utility of biomarker data. Moreover, a lack of proper analytical validation can potentially undermine successful demonstration of a biomarker-related pharmacodynamic effect during clinical investigation [1, 2]. Not surprisingly, successful biomarker testing in drug development requires careful consideration of pre-analytical factors that may impact reliable biomarker quantification in biological matrices. Most often, pre-analytical factors include activities associated involving collection, shipment, tracking, storage, and distribution of test samples. Analytical considerations include the use of kits versus custom assays, reference standard sourcing, sample preparation strategies [3, 4], instrumentation and the removal of matrix interferences. This chapter will discuss some of the various factors that need to be taken into account when preparing for biomarker analysis.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Bowsher R, Nowatzke W (2012) Application of commercial research-grade biomarker assays in drug development: is it time to create ‘pharmaceutical grade’ kits? Bioanalysis 4(20):2427–2430

    Article  CAS  PubMed  Google Scholar 

  2. Nowatzke W, Cole T, Bowsher R (2012) Systemic analytical validation of commercial kits for the determination of novel biomarkers for clinical drug development. Bioanalysis 2(2):237–247

    Article  Google Scholar 

  3. Tuck M et al (2013) Serum and plasma collection: preanalytical variables and standard operating procedures in biomarker research. Proteominc Metab Approaches Biomark Discov Chap 5:78–85

    Google Scholar 

  4. Ye X et al (2013) Tissue sample preparation for proteomic analysis. Proteominc Metab Approaches Biomark Discov Chap 3:40–49

    Google Scholar 

  5. Lee JW et al (2006) Fit-for-purpose method development and validation for successful biomarker measurement. Pharm Res 23(2):312–328

    Article  CAS  PubMed  Google Scholar 

  6. Holland N, Bastaki M et al (2005) Molecular epidemiology biomarkers—sample collection and processing considerations. Toxicol Appl Pharmacol 206:261–268

    Article  CAS  PubMed  Google Scholar 

  7. Tworoger S, Hankinson S et al (2006) Collection, processing, and storage of biological samples in epidemiologic studies: sex hormones, carotenoids, inflammatory markers, and proteomics as examples. Cancer Epidemiol Biomark Prev 15:1578–1581

    Article  CAS  Google Scholar 

  8. Campbell L (2012) Best practices for repositories: collection, storage, retrieval and distribution of biological materials for research. Biopreservation Biobanking 10:81–161

    Article  Google Scholar 

  9. National Metrology Laboratory (2012) User guide to mapping temperature controlled enclosures 4:1–8

    Google Scholar 

  10. Wagar EA, Stankovic AK, Raab S, Nakhleh RE, Walsh MK (2008) Specimen labeling errors: a Q-probes analysis of 147 clinical laboratories. Arch Pathol Lab Med 132(10):1617–1622

    Google Scholar 

  11. Tate J, Ward G (2004) Interferences in immunoassays. Clin Biochem Rev 25:105–120

    PubMed  PubMed Central  Google Scholar 

  12. Selby C (1999) Interference in immunoassay. Ann Clin Biochem 36:704–721

    Article  CAS  PubMed  Google Scholar 

  13. Kricka L (1999) Human anti-animal antibody interferences in immunological assays. Clin Chem 45:942–956

    CAS  PubMed  Google Scholar 

  14. Hamilton RG, Adkinson NF (1985) Naturally occurring carbohydrate antibodies: interference in solid-phase immunoassays. J Immunol Methods 77:95–108

    Article  CAS  PubMed  Google Scholar 

  15. Adedoyin J, Johansson SGO, Gronlund H, van Hage M (2006) Interference in immunoassays by human IgM with specificity for the carbohydrate moiety of animal proteins. J Immunol Methods 310:117–125

    Article  CAS  PubMed  Google Scholar 

  16. Levinson SS, Miller JJ (2002) Towards a better understanding of heterophile (and the like) antibody interferences with modern immunoassays. Clin Chim Acta 325:1–15

    Article  CAS  PubMed  Google Scholar 

  17. Bouvet JP, Quan CP, Dighiero G (2002) Polyreactivity is not an artifact. J Immunol Methods 254:199–201

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to R. Aleks Davis .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2016 American Association of Pharmaceutical Scientists

About this chapter

Cite this chapter

Davis, R.A., Mayer, A.P., Bowsher, R.R. (2016). Biomarkers in Drug Discovery and Development: Pre-analytical and Analytical Considerations. In: Weiner, R., Kelley, M. (eds) Translating Molecular Biomarkers into Clinical Assays . AAPS Advances in the Pharmaceutical Sciences Series, vol 21. Springer, Cham. https://doi.org/10.1007/978-3-319-40793-7_2

Download citation

Publish with us

Policies and ethics